<DOC>
	<DOC>NCT00523913</DOC>
	<brief_summary>This study is designed to evaluate the safety of BRL49653C administrated for 52 weeks</brief_summary>
	<brief_title>A Study Of BRL49653C For The Treatment Of Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Rosiglitazone</mesh_term>
	<criteria>Patients with type 2 diabetes mellitus managed by diet therapy or one antidiabetic agent (sulfonylurea or alpha glucosidase inhibitor) will be candidates for this study. These candidates will be checked up on their clinical laboratory data, and must have adequate blood, liver and kidney function. Patient with serious cardiovascular disease or serious hepatic disease will not be eligible.</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>type 2 diabetes mellitus;</keyword>
	<keyword>diabetes;</keyword>
	<keyword>rosiglitazone</keyword>
	<keyword>Avandia;</keyword>
</DOC>